Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RING - rituximab for lupus nephritis with persistent proteinuria despite standard care
2012-003314-13Phase 3Terminated
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: complete renal response. Started Aug 2012; status: terminated.
02
Drugs
rituximab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2012-003314-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003314-13.